Human Longevity, Inc. and Cleveland Clinic Establish Broad Collaboration in Human Genomics Human Longevity, Inc. and Cleveland Clinic announced a broad collaboration agreement to first sequence and analyze blood samples from Cleveland Clinic’s GeneBank study of de-identified patients. [Human Longevity, Inc.] Press Release Lilly and Sanford-Burnham Announce Collaboration to Investigate Immunological Therapies Eli Lilly and Company and Sanford-Burnham Medical Research Institute announced that they will collaborate to discover and develop immunological therapies. Lilly and Sanford-Burnham will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases such as lupus, Sjögren’s Syndrome, inflammatory bowel disease and other autoimmune disorders. [Eli Lilly and Company] Press Release Lilly and BioNTech Announce Research Collaboration on Novel Cancer Immunotherapies Eli Lilly and Company and BioNTech AG announced they have entered into a research collaboration to discover novel cancer immunotherapies. The companies will seek to use the power of the body’s own immune system to attack cancer cells and create possible new treatment options for cancer patients. [Eli Lilly and Company] Press Release Selecta and Généthon Collaborate to Create Next Generation Gene Therapies Using Selecta’s Synthetic Vaccine Particle Platform Selecta Biosciences, Inc. and Généthon announced an ongoing research collaboration with the goal of enabling repeat dosing for gene therapies. Based on preliminary results, the companies have identified three applications that might benefit from combining Généthon’s expertise in the development of gene therapy vectors and Selecta’s Synthetic Vaccine Particle platform to prevent undesired immune responses. [Selecta Biosciences, Inc.] Press Release Sanofi Exercises Option on Second Therapeutic Program with Selecta Biosciences to Develop an Antigen-Specific Immunotherapy Based on Synthetic Vaccine Particle Technology Selecta Biosciences, Inc. announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease. [Selecta Biosciences, Inc.] Press Release Argos Therapeutics Provides Update on Enrollment Progress for Ongoing Pivotal Phase III ADAPT Clinical Trial Argos Therapeutics Inc. announced that more than 1,000 tumor samples have been collected and approximately 400 eligible patients have been randomized to the company’s ongoing, pivotal Phase III ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma. [Argos Therapeutics Inc.] Press Release Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE® Smallpox Vaccine Bavarian Nordic A/S announced results from the first of two pivotal Phase III studies of the liquid-frozen formulation of IMVAMUNE® supporting a Biologics License Application for U.S. approval of the vaccine. [Bavarian Nordic A/S] Press Release NewLink Genetics’ IMPRESS Phase III Pancreatic Cancer Trial with Algenpantucel-L to Continue following Second Interim Analysis NewLink Genetics Corporation announced the continuation without any modification or sample size adjustment for its pivotal, Phase III IMmunotherapy for Pancreatic RESectable cancer Study, called “IMPRESS,” of algenpantucel-L for patients with surgically resected pancreatic cancer following the second planned interim data analysis. [NewLink Genetics Corporation] Press Release Alnylam Files Clinical Trial Application (CTA) for ALN-AAT, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease) Alnylam Pharmaceuticals, Inc. announced that it has filed a CTA with the U.K. Medicines and Healthcare products Regulatory Agency to initiate a Phase I/II clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 liver disease. [Alnylam Pharmaceuticals, Inc.] Press Release Pluristem’s PLX Cells One Step Closer to Entering Japan’s Accelerated Pathway for Regenerative Medicine Pluristem Therapeutics Inc. announced that Japan’s Pharmaceuticals and Medical Devices Agency agreed with the proposed quality and large-scale manufacturing methods for PLX-PAD cells for use in clinical trials. [Pluristem Therapeutics Inc.] Press Release |